trending Market Intelligence /marketintelligence/en/news-insights/trending/BMOYeoLijKQvJdT9_jyZ3Q2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Teva Pharmaceuticals faces patent infringement suit

Blog

Global M&A Infographic Q1 2021

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

Blog

COVID-19 Impact & Recovery: Private Equity

COVID-19 Impact & Recovery: Corporates


Teva Pharmaceuticals faces patent infringement suit

Aralez Pharmaceuticals Inc., two of its units and Pozen Inc. sued Teva Pharmaceuticals USA Inc., a unit of Teva Pharmaceutical Industries Ltd., for infringement of four patents covering Yosprala.

The suit, filed Jan. 23 in the U.S. District Court for the Eastern District of Texas, concerns an abbreviated new drug application filed by Teva with the U.S. FDA seeking approval to market generic versions of Yosprala prior to the expiration of the identified patents.

Three of the patents are listed in the approved drug products with therapeutic equivalence evaluations, known as the orange book, of the FDA. Pozen plans to list the fourth patent in the orange book.

Yosprala is a combination of aspirin and omeprazole, used to treat patients who need aspirin for secondary prevention of cardiovascular and cerebrovascular events and who are at risk of developing aspirin-associated gastric ulcers.